Home » Topics » Disease categories and therapies » Inflammatory

Inflammatory
RSS

AZD-9773 enters phase IIb trial in patients with severe sepsis and/or septic shock

Oct. 26, 2010

Almirall identifies new naphthyridine N-oxide as anti-inflammatory agent

Sep. 21, 2010

Positive outcome to decentralized procedure for European approval of Twinject

Sep. 1, 2010

Novel LPA1 receptor antagonists developed at Amira

July 7, 2010

Omeros selects clinical candidate for MASP-2 antibody program

May 14, 2010

Osiris achieves milestone for remestemcel-L development progress in Japan

April 29, 2010

DMC recommends continued enrollment in eritoran phase III trial for severe sepsis

March 26, 2010

Phase I trial of deferoxamine in acute cerebral hemorrhage currently recruiting participants

March 12, 2010

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...